ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LAD603

A development code.

Its studies are mostly in Alopecia Areata, led by Almirall.

Furthest: phase 2, since Dec 29, 20252 company-led studies, 1 open or runningNext primary completion: Jun 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Almirall21 open or runningphase 2since Dec 29, 2025Dec 22, 2023Jun 23, 2027phase 2 · NCT07311564

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT06200597 · 92 enrolled · United States
  2. Dec 29, 2025Phase 2 study in Alopecia AreataPhase 2 reachedNCT07311564 · 136 planned · United States

Ahead

  1. Jun 23, 2027Primary completion: phase 2 study in Alopecia AreataNCT07311564

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07311564Alopecia Areata · United States2RecruitingJun 23, 2027136
NCT06200597Healthy Volunteers · United States1CompletedMay 11, 202592

How it is read

Names in the registry

  • “LAD603”, 2 entries

Codes read as this program: LAD603.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.